UNSPSC 85266304: Diagnosis of organ-limited amyloidosis

This classification denotes the group of activities that yields a diagnosis of Organ-limited amyloidosis. Organ-limited amyloidosis is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as a four digit category under code E85. 4

UNSPSC 85266304 Diagnosis of organ-limited amyloidosis is a Commodity code that nominally addresses laboratory and clinical diagnostic procedures, but the recent state and local contract opportunities posted under this code do not align with amyloidosis-specific diagnostics. Instead, the three opportunities reflect a misclassification: San Mateo Medical Center's diagnostic imaging PACS (Picture Archiving and Communication System) procurement targets enterprise radiology, cardiology, and dental imaging infrastructure; Birdville Independent School District's special education contracted services solicitation covers audiologists, diagnosticians, and therapists; and Santa Clara Health System's temporary health professional staffing vehicle encompasses audiology, diagnostic imaging, and multiple ancillary clinical roles. None of these opportunities involves amyloidosis diagnosis or organ-limited amyloidosis protocols. The issuing bodies span county public health systems, school districts, and health authorities across California and Texas, but the scope mismatch between the code's nominal definition and the actual work being procured suggests either systematic miscoding or a code definition that does not reflect current state and local procurement taxonomy usage.

The three posted opportunities carry response dates in late September and October 2026: San Mateo Medical Center's PACS RFP closed October 21, 2026; Birdville ISD's special education services RFQ also closed October 21, 2026; and Santa Clara Health System's staffing qualification RFQ closed October 7, 2026. Geographic activity appears concentrated in California and Texas. The code shows recent activity, but the fundamental disconnect between the code title (organ-limited amyloidosis diagnosis) and the procurement content (imaging systems, school-based therapies, and clinical staffing) indicates that this Commodity code is not capturing genuine amyloidosis diagnostic work in current state and local markets, and business development professionals should verify correct code classification before committing pursuit resources to opportunities listed under this category.